Ex-Vivo磁気共鳴画像法を用いたヒト脳の定量的感受性マッピング

Executive Industry Relevance

Quantitative susceptibility mapping (QSM) using ex-vivo MRI enables precise quantification of brain tissue magnetic properties, directly informing cellular composition such as myelin content. This capability supports mechanistic de-risking and target validation in neurodegeneration and demyelination research. Integrating artifact-suppressed QSM data enhances predictive confidence at key discovery and preclinical inflection points.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables quantitative interrogation of tissue composition relevant to neurological targets.
• Supports biological de-risking by distinguishing myelin and iron content in brain regions.
• Facilitates predictive confidence in target engagement and mechanism-of-action studies.

Screening & Assay Development

• Provides validated imaging readouts for downstream assay development.
• Standardizes artifact removal and signal enhancement for reproducible outputs.
• Enables robust comparison of compound effects on tissue susceptibility in screening workflows.

Translational & Preclinical Research

• Aligns imaging biomarkers with disease-relevant tissue changes in preclinical models.
• Supports continuity from discovery through preclinical validation by quantifying tissue alterations.
• Improves risk-adjusted advancement decisions based on quantitative imaging endpoints.

Pipeline & Workflow Integration

QSM integrates into the neuroimaging discovery continuum, bridging early discovery, lead identification, and preclinical research with quantitative, reproducible tissue characterization.

• Discovery Biology: Quantifies tissue susceptibility to clarify mechanistic hypotheses and validate targets.
• Screening: Delivers standardized, artifact-suppressed imaging outputs for assay readiness.
• Analytics: Provides quantitative phase and susceptibility maps for cross-condition comparison.
• Translational Research: Links imaging findings to disease-relevant tissue changes in preclinical models.
• Enterprise Reuse: Establishes a reproducible imaging workflow adaptable across neurodegenerative research programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuroimaging studies.
• Operational Value: Standardizes artifact removal and data processing for reproducibility and scalability.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
• Portfolio Impact: Supports risk-adjusted prioritization of neurological targets and programs.

Implementation Considerations

• Requires expertise in MRI acquisition and advanced data processing algorithms.
• Demands access to high-field MRI instrumentation and specialized software tools.
• Necessitates cross-team standardization of artifact removal and phase mapping protocols.
• Adaptation may be needed for different tissue types or disease models.
• Artifact suppression and signal enhancement are critical for reliable quantitative outputs.

Biopharma FAQs